Jei-Ming Peng

Jei-Ming Peng is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer research, particularly in the area of metastasis. With a total of 4 patents, his work focuses on innovative methods to combat cancer progression.

Latest Patents

One of his latest patents is titled "Suppression of Cancer Metastasis." This invention provides methods for using fibrillar proteins to suppress cancer metastasis, which is a leading cause of treatment failure and death among cancer patients. The research demonstrates that tumor cell invasion and migration can be significantly inhibited after treatment with fibrillar proteins such as rVP1, F-HSA, and F-BSA in vitro. Furthermore, rVP1 has shown promising results in significantly suppressing murine and human breast cancer metastasis, as well as human prostate and ovarian cancer metastasis in vivo. Another notable patent is "Apoptosis-Inducing Polypeptides," which involves an isolated water-soluble VP1 polypeptide from the foot-and-mouth disease virus and a nucleic acid encoding this polypeptide. This invention also includes a pharmaceutical composition containing the polypeptide or nucleic acid, along with methods for inducing apoptosis and treating apoptosis-related disorders.

Career Highlights

Jei-Ming Peng is affiliated with Academia Sinica, a prestigious research institution in Taiwan. His work has garnered attention for its potential impact on cancer treatment and understanding the mechanisms of metastasis.

Collaborations

He has collaborated with notable colleagues, including Shu-Mei Liang and Chi-Ming Liang, to advance research in his field.

Conclusion

Jei-Ming Peng's innovative work in cancer research exemplifies the importance of scientific advancements in combating serious health challenges. His patents reflect a commitment to improving treatment outcomes for cancer patients.

This text is generated by artificial intelligence and may not be accurate.